CoChat
Sign Up
Cited by 12

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

The Gut Microbiome and Metastatic Renal Cell Carcinoma

Meza, Luis, Feng, Matthew, Lee, Kyle, Sperandio, Rubens, Pal, Sumanta Kumar·2023·Journal of Clinical Medicine
DOI 10.3390/jcm12041502PMC PMC9960560
Open this paper in CoChat — free account

Abstract

The introduction of targeted therapy (TT) and immuno-oncology (IO) agents have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). However, despite the significant improvements in survival and clinical response yielded by these agents, a significant percentage of patients still experience progressive disease. Evidence now suggests that microorganisms living in the gut (i.e., the gut microbiome) could be used as a biomarker for response and may also have utility in increasing response to these treatments. In this review, we present an overview of the role of the gut microbiome in cancer and its potential implications in the treatment of mRCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm12041502

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design for the phase I cabozantinib plus nivolumab +/− CBM588 trial [97].
Figure 1 Study design for the phase I cabozantinib plus nivolumab +/− CBM588 trial [97].CC BY · PubMed Central
Figure 2 Study design for the KETOREIN trial.
Figure 2 Study design for the KETOREIN trial.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 78

  1. Motzer, 2007, Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, N. Engl. J. Med., 356, 115, 10.1056/NEJMoa065044 · DOI
  2. Sternberg, 2010, Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, J. Clin. Oncol., 28, 1061, 10.1200/JCO.2009.23.9764 · DOI
  3. Rini, 2011, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial, Lancet, 378, 1931, 10.1016/S0140-6736(11)61613-9 · DOI
  4. Choueiri, 2017, Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial, J. Clin. Oncol., 35, 591, 10.1200/JCO.2016.70.7398 · DOI
  5. Motzer, 2015, Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial, Lancet Oncol., 16, 1473, 10.1016/S1470-2045(15)00290-9 · DOI
  6. Hudes, 2007, Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 356, 2271, 10.1056/NEJMoa066838 · DOI
  7. Meza, 2022, Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma, Futur. Oncol., 18, 21, 10.2217/fon-2021-0570 · DOI
  8. Dudani, 2020, An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma, Eur. Urol. Focus, 6, 34, 10.1016/j.euf.2019.04.004 · DOI
  9. Zitvogel, 2021, The microbiome and human cancer, Science, 371, eabc4552, 10.1126/science.abc4552 · DOI · Paper page
  10. Bianconi, 2013, An estimation of the number of cells in the human body, Ann. Hum. Biol., 40, 463, 10.3109/03014460.2013.807878 · DOI · Paper page
  11. Sender, R., Fuchs, S., and Milo, R. (2016). Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLOS Biol., 14. · DOI
  12. Thomas, 2017, The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists, Cancer Res., 77, 1783, 10.1158/0008-5472.CAN-16-2929 · DOI
  13. Schluter, 2020, The gut microbiota is associated with immune cell dynamics in humans, Nature, 588, 303, 10.1038/s41586-020-2971-8 · DOI · Paper page
  14. Mazmanian, 2005, An Immunomodulatory Molecule of Symbiotic Bacteria Directs Maturation of the Host Immune System, Cell, 122, 107, 10.1016/j.cell.2005.05.007 · DOI · Paper page
  15. Olin, 2018, Stereotypic Immune System Development in Newborn Children, Cell, 174, 1277, 10.1016/j.cell.2018.06.045 · DOI
  16. Tan, 2016, Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice, Proc. Natl. Acad. Sci. USA, 113, E8141, 10.1073/pnas.1617460113 · DOI · Paper page
  17. Deshmukh, 2014, The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice, Nat. Med., 20, 524, 10.1038/nm.3542 · DOI · Paper page
  18. Ivanov, 2008, Specific Microbiota Direct the Differentiation of IL-17-Producing T-Helper Cells in the Mucosa of the Small Intestine, Cell Host Microbe, 4, 337, 10.1016/j.chom.2008.09.009 · DOI · Paper page
  19. Sefik, 2017, Mining the Human Gut Microbiota for Immunomodulatory Organisms, Cell, 168, 928, 10.1016/j.cell.2017.01.022 · DOI · Paper page
  20. Zaneveld, 2008, Host-bacterial coevolution and the search for new drug targets, Curr. Opin. Chem. Biol., 12, 109, 10.1016/j.cbpa.2008.01.015 · DOI
  21. Khan, 2022, Circulating microbiota and metabolites: Insights into cardiovascular diseases, J. Clin. Lab. Anal., 36, e24779, 10.1002/jcla.24779 · DOI
  22. Arze, 2019, Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases, Nature, 569, 655, 10.1038/s41586-019-1237-9 · DOI · Paper page
  23. Azzouz, 2019, Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal, Ann. Rheum. Dis., 78, 947, 10.1136/annrheumdis-2018-214856 · DOI
  24. Kong, 2020, Linking Strain Engraftment in Fecal Microbiota Transplantation with Maintenance of Remission in Crohn’s Disease, Gastroenterology, 159, 2193, 10.1053/j.gastro.2020.08.045 · DOI · Paper page
  25. Rous, 1911, A Sarcoma of the Fowl Transmissible by an Agent Separable from the Tumor Cells, J. Exp. Med., 13, 397, 10.1084/jem.13.4.397 · DOI · Paper page
  26. Yang, 2022, Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012–2021), Front. Immunol., 13, 952546, 10.3389/fimmu.2022.952546 · DOI
  27. White, 2014, Viruses and Human Cancers: A Long Road of Discovery of Molecular Paradigms, Clin. Microbiol. Rev., 27, 463, 10.1128/CMR.00124-13 · DOI
  28. Knippel, 2021, The Cancer Microbiome: Recent Highlights and Knowledge Gaps, Cancer Discov., 11, 2378, 10.1158/2159-8290.CD-21-0324 · DOI
  29. Park, 2022, Targeting the gut and tumor microbiota in cancer, Nat. Med., 28, 690, 10.1038/s41591-022-01779-2 · DOI · Paper page
  30. Brennan, 2016, Gut Microbiota, Inflammation, and Colorectal Cancer, Annu. Rev. Microbiol., 70, 395, 10.1146/annurev-micro-102215-095513 · DOI
  31. Yang, 2017, Novel insights into microbiome in colitis and colorectal cancer, Curr. Opin. Gastroenterol., 33, 422, 10.1097/MOG.0000000000000399 · DOI
  32. Mei, 2022, Dysbiosis: The first hit for digestive system cancer, Front. Physiol., 13, 1040991, 10.3389/fphys.2022.1040991 · DOI
  33. Mima, 2017, The microbiome and hepatobiliary-pancreatic cancers, Cancer Lett., 402, 9, 10.1016/j.canlet.2017.05.001 · DOI
  34. Wu, 2022, Elevated bile acid metabolism and microbiome are associated with suppressed cell proliferation and better survival in breast cancer, Am. J. Cancer Res., 12, 5271
  35. Mekadim, C., Skalnikova, H.K., Cizkova, J., Cizkova, V., Palanova, A., Horak, V., and Mrazek, J. (2022). Dysbiosis of skin microbiome and gut microbiome in melanoma progression. BMC Microbiol., 22. · DOI
  36. Viaud, 2013, The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide, Science, 342, 971, 10.1126/science.1240537 · DOI · Paper page
  37. Iida, 2019, Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment, Science, 342, 967, 10.1126/science.1240527 · DOI · Paper page
  38. Simpson, 2022, Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome, Nat. Med., 28, 2344, 10.1038/s41591-022-01965-2 · DOI · Paper page
  39. Liu, 2021, Intestinal Microbiome Associated with Immune-Related Adverse Events for Patients Treated with Anti-PD-1 Inhibitors, a Real-World Study, Front. Immunol., 12, 5334, 10.3389/fimmu.2021.756872 · DOI
  40. Fernandes, 2022, Targeting the gut microbiota for cancer therapy, Nat. Rev. Cancer, 22, 703, 10.1038/s41568-022-00513-x · DOI · Paper page
  41. Tomita, 2020, Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer, Cancer Immunol. Res., 8, 1236, 10.1158/2326-6066.CIR-20-0051 · DOI · Paper page
  42. Lythgoe, 2022, Polymorphic microbes: A new emerging hallmark of cancer, Trends Microbiol., 30, 1131, 10.1016/j.tim.2022.08.004 · DOI
  43. Hanahan, 2022, Hallmarks of Cancer: New Dimensions, Cancer Discov., 12, 31, 10.1158/2159-8290.CD-21-1059 · DOI · Paper page
  44. Helmink, 2019, The microbiome, cancer, and cancer therapy, Nat. Med., 25, 377, 10.1038/s41591-019-0377-7 · DOI · Paper page
  45. Yoon, 2021, Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice, Nat. Microbiol., 6, 563, 10.1038/s41564-021-00880-5 · DOI · Paper page
  46. Derosa, 2021, Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?, Cancer Discov., 11, 2396, 10.1158/2159-8290.CD-21-0236 · DOI · Paper page
  47. Okumura, 2021, Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion, Nat. Commun., 12, 5674, 10.1038/s41467-021-25965-x · DOI
  48. Rossi, T., Vergara, D., Fanini, F., Maffia, M., Bravaccini, S., and Pirini, F. (2020). Microbiota-Derived Metabolites in Tumor Progression and Metastasis. Int. J. Mol. Sci., 21. · DOI
  49. Blake, 2021, The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota, Cell Rep. Med., 2, 100464, 10.1016/j.xcrm.2021.100464 · DOI
  50. Furusawa, 2013, Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells, Nature, 504, 446, 10.1038/nature12721 · DOI · Paper page
  51. Makki, 2018, The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease, Cell Host Microbe, 23, 705, 10.1016/j.chom.2018.05.012 · DOI · Paper page
  52. Morrison, 2016, Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism, Gut Microbes, 7, 189, 10.1080/19490976.2015.1134082 · DOI · Paper page
  53. Kespohl, 2017, The Microbial Metabolite Butyrate Induces Expression of Th1-Associated Factors in CD4+ T Cells, Front. Immunol., 8, 1036, 10.3389/fimmu.2017.01036 · DOI · Paper page
  54. Luu, 2018, Regulation of the effector function of CD8+ T cells by gut microbiota-derived metabolite butyrate, Sci. Rep., 8, 14430, 10.1038/s41598-018-32860-x · DOI
  55. Salvi, P.S., and Cowles, R.A. (2021). Butyrate and the Intestinal Epithelium: Modulation of Proliferation and Inflammation in Homeostasis and Disease. Cells, 10. · DOI
  56. Bordonaro, 2001, Cell type- and promoter-dependent modulation of the Wnt signaling pathway by sodium butyrate, Int. J. Cancer, 97, 42, 10.1002/ijc.1577 · DOI
  57. Bordonaro, 2008, Role of Tcf-DNA binding and the chromatin remodeling factor Brg-1 in the modulation of Wnt activity by butyrate, Cell Cycle, 7, 3472, 10.4161/cc.7.21.6933 · DOI
  58. Mandal, 2001, Butyric acid induces apoptosis by up-regulating Bax expression via stimulation of the c-Jun N-terminal kinase/activation protein-1 pathway in human colon cancer cells, Gastroenterology, 120, 71, 10.1053/gast.2001.20897 · DOI
  59. Thangaraju, 2009, GPR109A Is a G-protein–Coupled Receptor for the Bacterial Fermentation Product Butyrate and Functions as a Tumor Suppressor in Colon, Cancer Res., 69, 2826, 10.1158/0008-5472.CAN-08-4466 · DOI · Paper page
  60. Chen, 2019, Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota, Cancer Lett., 469, 456, 10.1016/j.canlet.2019.11.019 · DOI
  61. McDermott, 2018, Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma, Nat. Med., 24, 749, 10.1038/s41591-018-0053-3 · DOI · Paper page
  62. Garon, 2015, Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer, N. Engl. J. Med., 372, 2018, 10.1056/NEJMoa1501824 · DOI · Paper page
  63. Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 · DOI · Paper page
  64. Albiges, 2020, Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial, ESMO Open, 5, e001079, 10.1136/esmoopen-2020-001079 · DOI
  65. Sivan, 2015, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, 350, 1084, 10.1126/science.aac4255 · DOI · Paper page
  66. Balan, 2015, Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression, J. Biol. Chem., 290, 8110, 10.1074/jbc.M114.612689 · DOI
  67. Paolino, M., and Penninger, J.M. (2016). The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy. Cancers, 8. · DOI
  68. Voron, 2014, Control of the Immune Response by Pro-Angiogenic Factors, Front. Oncol., 4, 70, 10.3389/fonc.2014.00070 · DOI
  69. Hughes, 2016, Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer, Trends Immunol., 37, 462, 10.1016/j.it.2016.04.010 · DOI
  70. Meza, 2022, A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC), J. Clin. Oncol., 40, TPS4606, 10.1200/JCO.2022.40.16_suppl.TPS4606 · DOI
  71. Meza, 2022, Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma, Clin. Transl. Med., 12, e948, 10.1002/ctm2.948 · DOI
  72. Ninkov, M., Schmerk, C.L., Moradizadeh, M., Parvathy, S.N., Figueredo, R., Burton, J.P., Silverman, M.S., Fernandes, R., Vareki, S.M., and Haeryfar, S.M.M. (2022). Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma. Cancer Immunol. Immunother., 1–14. · DOI
  73. Ianiro, 2020, Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma, Nat. Commun., 11, 4333, 10.1038/s41467-020-18127-y · DOI
  74. Ferrere, 2021, Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade, J. Clin. Investig., 6, e145207
  75. Huttenhower, 2016, The healthy human microbiome, Genome Med., 8, 51, 10.1186/s13073-016-0307-y · DOI · Paper page
  76. Qin, 2010, A human gut microbial gene catalogue established by metagenomic sequencing, Nature, 464, 59, 10.1038/nature08821 · DOI · Paper page
  77. Qin, 2012, A metagenome-wide association study of gut microbiota in type 2 diabetes, Nature, 490, 55, 10.1038/nature11450 · DOI · Paper page
  78. Li, 2022, Gut microbiome in modulating immune checkpoint inhibitors, Ebiomedicine, 82, 104163, 10.1016/j.ebiom.2022.104163 · DOI

Cited by

Sorted by citations

See all 12

Metadata

Authors
Meza, L., Feng, M., Lee, K., Sperandio, R., & Pal, S. K.
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2023-02-14
Volume
12
Issue
4
Pages
1502
ISSN
2077-0383
DOI
10.3390/jcm12041502
PMC
PMC9960560
Cited by
12
References
26
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review